Researchers are excitedly examining retatrutide, a innovative treatment from Eli Lilly, as a possible advance in body loss . Different than many previous approaches, retatrutide is a dual -action receptor targeting simultaneously GLP-1 and GIP, hormones that impact satiety and glucose control . E